RPC opinion: restricting gonadotrophin-releasing hormone analogues
Regulatory Policy Committee's opinion of the quality of the evidence and analysis in the impact assessment from Department of Health and Social Care.
Documents
Details
The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Restrictions on Private Sales and Supplies) Order 2024 implements an indefinite ban on the sale and supply of puberty blockers to under 18s by private UK providers and prescribers in the European Economic Area and Switzerland.
The Regulatory Policy Committee (RPC) gave a ‘green’ rating to the impact assessment on 10 February 2025. This means that we considered it to be fit for purpose based on our scrutiny of the evidence and analysis supporting the case for why regulation is necessary.
The RPC’s opinion refers to the evidence and analysis presented in the impact assessment, not the policy itself.